As its role in the immune response is more well-defined than NF-κB, targeting p53 LOF-mediated STAT3 activation to suppress both STAT3 and NF-κB pro-cancer signaling may be a viable approach to inducing an anti-tumor immune response. The gene discussed is STAT3; the disease is neoplasm.